KOD — Kodiak Sciences Inc

Is KOD overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of August 19, 2026

Kodiak Sciences Inc (KOD) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $40.07. The rating moved from Neutral to Oversold on August 13, 2026.

See all oversold Healthcare stocks →

AI analysis

Kodiak Sciences Inc (KOD) is a clinical-stage biotech whose valuation is driven primarily by pipeline progress and capital position. Near-term market conditions are neutral and sector themes around biologics/CDMO suppliers are supportive at the macro level, but the company’s intrinsic performance will hinge on trial readouts, regulatory milestones, and funding availability. Given limited public filing detail in the provided window, outcomes are scenario-driven and exposure to binary clinical/regulatory events remains the dominant driver of near-term price moves.

Key factors

  • Early-stage / clinical-stage biotech profile with pipeline-driven valuation that depends on trial readouts and regulatory milestones
  • Sector tailwinds for biologics and CDMO demand could indirectly benefit partners and suppliers, but direct readthrough to company revenue is limited until commercialization
  • Cash runway and capital structure are key near-term determinants of dilution risk and ability to complete development programs
  • Limited current commercial revenue; value is concentrated in clinical and regulatory progress which creates binary upside tied to successful outcomes
  • Broader market tone is balanced with selective growth interest; no major macro or geopolitical shocks in the short window observed
  • Lack of recent EDGAR/filing detail in the supplied data increases uncertainty about near-term catalysts and financial health

Risks

  • Clinical trial failures, inconclusive data, or regulatory setbacks that could sharply reduce valuation
  • Need for additional capital leading to equity dilution or unfavorable financing terms
  • Competitive pressures from larger biopharma companies or faster-moving programs in the same indications
  • Commercial execution risk if/when products approach approval, including payer resistance and market access challenges
  • Volatility in biotech sector sentiment and swings driven by macro/rate expectations or sector rotation
  • Limited social sentiment data available increases information asymmetry for short-term investor positioning

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for KOD — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.